Phase 1b/2 study of the combination of BL-8040 with atezolizumab in patients with pancreatic cancer.

Trial Profile

Phase 1b/2 study of the combination of BL-8040 with atezolizumab in patients with pancreatic cancer.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; BL 8040 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 26 Sep 2017 According to a BioLineRx media release, this trial is expected to begin by the end of 2017.
    • 26 Sep 2017 According to a BioLineRx media release, this study is under BioLineRx's cancer immunotherapy collaboration with Genentech to conduct several Phase 1b/2 studies investigating the combination of BL-8040 with atezolizumab in multiple cancer indications, announced in September 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top